Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019
Recruiting
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to \<12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDLC).
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
07/28/2025
Locations: UC San Francisco Medical Center, San Francisco, California +54 locations
Conditions: Familial Hypercholesterolemia - Heterozygous
Register for Updates
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
NCT06602193
Recruiting
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/28/2025
Locations: Cedars-Sinai Department of Neurology, Los Angeles, California +15 locations
Conditions: Parkinson Disease
Register for Updates
A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
NCT06602453
Recruiting
The aim of this study is to evaluate the efficacy and safety of GDC-8264 compared with placebo in participants undergoing cardiac surgery who are determined to be at moderate to high risk of developing AKI and subsequent MAKE at 90 days after surgery (MAKE90). The study will be performed in two parts- Part 1 and Part 2.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/28/2025
Locations: Ronald Reagan UCLA Medical Center, Los Angeles, California +30 locations
Conditions: Acute Kidney Injury
Register for Updates
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775
Recruiting
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: University of California Los Angeles, Los Angeles, California +12 locations
Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, HER2-Positive Advanced Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer
Register for Updates
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908
Recruiting
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +8 locations
Conditions: Advanced Solid Tumor
Register for Updates
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/28/2025
Locations: UCSF, San Francisco, California +46 locations
Conditions: Scleroderma, Diffuse
Register for Updates
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
NCT06665100
Recruiting
The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: City of Hope National Medical Center, Duarte, California +9 locations
Conditions: Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Register for Updates
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256
Recruiting
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/28/2025
Locations: Northwestern University, Chicago, Illinois +29 locations
Conditions: Idiopathic Inflammatory Myopathies
Register for Updates
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/28/2025
Locations: Study Site, Little Rock, Arkansas +51 locations
Conditions: Hereditary Angioedema (HAE)
Register for Updates
Infectious Disease (ID) Testing OUtreach in Carceral Hubs
NCT06679751
Recruiting
This pilot feasibility study represents part 3 of a larger R61 study, where the investigators will follow a cohort about their experiences with human immunodeficiency virus (HIV) testing. This project aims to assess the effectiveness of an intervention at two jail sites in the Boston area: South Bay House of Corrections and Nashua Street Jail implemented in January of 2025 that is aimed at improving HIV testing practices and HIV treatment in those carceral facilities. This implementation was de... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: South Bay House of Corrections, Boston, Massachusetts
Conditions: HIV Infections, Opioid Use Disorder
Register for Updates
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881
Recruiting
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/28/2025
Locations: Study Site, Santa Monica, California +16 locations
Conditions: Hereditary Angioedema (HAE)
Register for Updates
Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes
NCT06735651
Recruiting
The goal of this clinical trial is to determine the effectiveness of using a freeze-dried wild blueberry powder on cardiometabolic health, cognitive function, and gut microbiota composition in adult women with prediabetes.
Gender:
FEMALE
Ages:
Between 45 years and 65 years
Trial Updated:
07/28/2025
Locations: Georgia State University, Atlanta, Georgia
Conditions: Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (reactive Hyperemia), Arterial Stiffness, Cognition, Oxidative Stress, Gut Microbiota, Overweight, Inflammation, Microvascular Function, Body Composition
Register for Updates